R&D channel feed

The R&D 15: Top phar­ma play­ers shell out record $153B for re­search, and M&A is a prime fo­cus for all

Last year
Bioregnum
Special

As place­bo spoils PhI­II tri­al, Aca­dia does not in­tend to stage fur­ther Nu­plazid stud­ies in schiz­o­phre­nia

Last year

Lex­i­con gears up for an­oth­er shot in di­a­betes as path for­ward agreed with FDA

Last year
Pharma

#AAD24 roundup: Da­ta from Sanofi, Alu­mis, Gal­der­ma and more

Last year

Moon­Lake out­lines more da­ta in pso­ri­at­ic arthri­tis as it preps for piv­otal tri­als: #AAD24

Last year

As J&J's oral IL-23 takes on So­tyk­tu, one-year fol­low-up da­ta show dura­bil­i­ty: #AAD24

Last year

No­var­tis of­fers glimpse at BTK in­hibitor plans be­yond lead in­di­ca­tions: #AAD24

Last year

Akero ex­ec­u­tives point to ad­vanced fi­bro­sis pa­tients for MASH drug

Last year
Pharma

The FDA al­most nev­er pulls ful­ly-ap­proved drugs. Amy­lyx's ALS treat­ment might be the ex­cep­tion

Last year
FDA+

Macro­Gen­ics, Ab­b­Vie stop de­vel­op­ment of part­nered ADC

Last year
Deals

Amy­lyx's ALS treat­ment Re­lyvrio fails PhI­II study, biotech to con­sid­er with­draw­ing drug

Last year

Kro­nos Bio cuts a fifth of staff, ex­plores new dos­ing sched­ule for sol­id tu­mor drug

Last year
People

David Bak­er's lab re­leas­es new pro­tein de­sign and study tools as AI race ac­cel­er­ates

Last year
AI
Discovery

Bris­tol My­ers nabs ap­proval for Op­di­vo com­bo as first-line blad­der can­cer treat­ment

Last year
Pharma
FDA+

Up­dat­ed: Even with no pri­ma­ry end­point da­ta, Tau­Rx still eyes Alzheimer’s fil­ing af­ter PhI­II up­date

Last year

No­vo touts ear­ly da­ta for next-gen oral weight loss drug as it out­lines next steps

Last year
Pharma

Mer­ck KGaA to fo­cus on ‘ex­ter­nal in­no­va­tion’ as it ex­its BTK in­hibitor race

Last year
Deals

GSK de­clares sec­ond PhI­II win for Blenrep com­bo in bid to re­vive drug

Last year

Third anti­gen's a charm: Gilead pens deal with Merus for up to three trispe­cif­ic an­ti­bod­ies 

Last year
Deals

Alu­mis clos­es a $259M Se­ries C to back its TYK2, flirts with talk about an IPO

Last year
Financing

Re­genxbio gives glimpse at ear­ly Duchenne gene ther­a­py re­sults, plans piv­otal study for ac­cel­er­at­ed ap­proval

Last year
Cell/Gene Tx

Roche, Al­ny­lam’s zilebe­sir­an suc­ceeds in an­oth­er PhII hy­per­ten­sion test

Last year

Amy­lyx read­ies for make-or-break PhI­II, look­ing to ad­dress un­cer­tain­ty over con­tro­ver­sial ALS drug

Last year
Pharma
In Focus

Bay­er on job cuts, pipeline gaps, obe­si­ty and Mon­san­to lit­i­ga­tion as ex­ecs de­fend keep­ing cur­rent struc­ture

Last year
Pharma
First page Previous page 49505152535455 Next page Last page
A service from the Financial Times